Chinese biotechnology company DualityBio (HKEX:9606) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310.
This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. First-in-human Phase I/IIa clinical trial data of DB-1310 demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumours who had failed standard therapies.
Akeso enrols first patient in Phase III ivonescimab trial for pancreatic cancer
AN2 Therapeutics and DNDi partner to advance oral therapy for chronic Chagas disease
Enveric Biosciences secures second US patent allowance for non-hallucinogenic mescaline derivatives
Lantern Pharma reports first complete response with LP-284 in heavily pretreated lymphoma patient
Hoth Therapeutics Ppartners with VA to evaluate GDNF for obesity and fatty liver disease
AstraZeneca announces USD50bn US investment to expand manufacturing and R&D footprint
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
AusperBio receives Chinese regulatory approval for Phase III trial of AHB-137 in chronic hepatitis B
DualityBio's HER3 ADC DB-1310 granted US FDA Fast Track Designation
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic